ICH guideline E2C (R2) on periodic benefit-risk evaluation report (PBRER)

We have adopted this International Scientific Guideline – ICH E2C (R2); EMA/CHMP/ICH/544553/1998

Last updated

29 August 2024

About this guideline

Overseas effective date: January 2013

Replaces: CPMP/ICH/4679/02 (Addendum to ICH E2C - CPMP/ICH/288/95)

Categories: ICH | Efficacy | Clinical safety

TGA Annotations: Nil

Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.

Product types